within Pharmacolibrary.Drugs.ATC.A;

model A02BX12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 1.6666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BX12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bismuth subnitrate is an inorganic bismuth salt formerly used as an antacid and mild astringent in the treatment of gastric and duodenal ulcers and gastritis. It is now largely obsolete and rarely used in modern medicine due to safety and efficacy concerns; other bismuth compounds or pharmacological treatments are preferred.</p><h4>Pharmacokinetics</h4><p>No specific human pharmacokinetic studies or published compartmental models for bismuth subnitrate have been identified in the scientific literature. PK parameters are estimated based on known physicochemical properties and similarity to other insoluble bismuth salts; oral absorption in humans is negligible due to very low solubility, and systemic exposure is expected to be minimal or absent.</p><h4>References</h4><ol><li><p>Slikkerveer, A, &amp; de Wolff, FA (1989). Pharmacokinetics and toxicity of bismuth compounds. <i>Medical toxicology and adverse drug experience</i> 4(5) 303–323. DOI:<a href=\"https://doi.org/10.1007/BF03259915\">10.1007/BF03259915</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2682129/\">https://pubmed.ncbi.nlm.nih.gov/2682129</a></p></li><li><p>Pamphlett, R, et al., &amp; Danscher, G (2000). Uptake of bismuth in motor neurons of mice after single oral doses of bismuth compounds. <i>Neurotoxicology and teratology</i> 22(4) 559–563. DOI:<a href=\"https://doi.org/10.1016/s0892-0362(00)00083-0\">10.1016/s0892-0362(00)00083-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10974594/\">https://pubmed.ncbi.nlm.nih.gov/10974594</a></p></li><li><p>Morikawa, T, &amp; Kawamura, E (1989). [A method of cisplatin administration with the aid of high-dose bismuth subnitrate, and their pharmacokinetics]. <i>Gan to kagaku ryoho. Cancer &amp; chemotherapy</i> 16(4 Pt 2-1) 1094–1098. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2730014/\">https://pubmed.ncbi.nlm.nih.gov/2730014</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BX12;
